Brief: Orphazyme Publishes Positive Results From Phase 2 Trial Of Arimoclomol

Strategic Partners A/S

23/08/2021 10:26

Aug 23 (Reuters) - Orphazyme A/S  ORPHA.CO :
    * ORPHAZYME ANNOUNCES PUBLICATION OF RESULTS FROM ITS PHASE
2/3
TRIAL OF ARIMOCLOMOL IN NIEMANN-PICK DISEASE TYPE C IN THE
JOURNAL OF INHERITED METABOLIC DISEASE
    * TRIAL DEMONSTRATED A STATISTICALLY SIGNIFICANT AND
CLINICALLY
MEANINGFUL TREATMENT EFFECT OF ARIMOCLOMOL IN NPC
    * ARIMOCLOMOL WAS WELL-TOLERATED, WITH ADVERSE EVENTS
OCCURRING IN
88.2% OF PATIENTS RECEIVING ARIMOCLOMOL AND 75.0% OF PATIENTS
RECEIVING PLACEBO
    * ARIMOCLOMOL IS UNDER REGULATORY REVIEW IN EUROPE, WITH AN
ANTICIPATED CHMP OPINION IN Q4 2021
    * WE CONTINUE TO EVALUATE PATH FORWARD IN U.S. FOLLOWING
RECENT
FDA RESPONSE
    * WE BELIEVE THESE DATA ESTABLISH POTENTIAL OF ARIMOCLOMOL
AS AN
EFFICACIOUSAND WELL-TOLERATED DISEASE-MODIFYING TREATMENT FOR
NPC

Source text for Eikon:  ID:nGNEfL8K3 
Further company coverage:  ORPHA.CO 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))